title: Pregnancy outcome after chelation therapy in Wilson disease. Evaluation of the German Embryotox Database.
abstract: Continuation of treatment is recommended for pregnant women with Wilson disease. Therapy options include the copper chelating agents d-penicillamine and trientine. However, there are still uncertainties concerning a possible teratogenic risk. In this case series, we report on the outcome of 20 pregnancies with maternal chelator exposure at least during the first trimester. Of these 20 pregnancies documented by the German Embryotox Project, 14 were prospectively ascertained and 6 were retrospective. No major birth defects were observed. Three of the 14 prospective cases resulted in a spontaneous abortion, and one pregnancy was electively terminated. Our results do not support the hypothesis of teratogenicity based on earlier case reports of congenital anomalies. Therefore our study may contribute to reassure women needing chelation therapy during pregnancy. However, it must be taken into account that the sample size of this case series is too limited to make final conclusions on teratogenic effects.
authors.affiliation: Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Charité-Universitätsmedizin, Berlin, Germany. Electronic address: katarina.dathe@charite.de.
authors.forename: Katarina
authors.initials: K
authors.lastname: Dathe
authors.affiliation: Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Charité-Universitätsmedizin, Berlin, Germany.
authors.forename: Evelin
authors.initials: E
authors.lastname: Beck
authors.affiliation: Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Charité-Universitätsmedizin, Berlin, Germany.
authors.forename: Christof
authors.initials: C
authors.lastname: Schaefer
mesh_terms: D000328:Adult; D002614:Chelating Agents / Q000627:therapeutic use*; D015913:Chelation Therapy; D003300:Copper; D016208:Databases, Factual; D005260:Female; D005858:Germany; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D010396:Penicillamine / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D014266:Trientine / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D002614:Chelating Agents; D003300:Copper; D010396:Penicillamine; D014266:Trientine
keywords: Chelation therapy; Penicillamine; Pregnancy outcome; Trientine; Wilson disease